Telix Doses First Patient in Pioneering ZOLAR Trial for Advanced Soft Tissue Sarcoma
April 02, 2025 | 11:05
Telix Pharmaceuticals Limited today announces that a first patient has been dosed in the Phase 1 ZOLAR[1] trial of TLX300-CDx (89Zr-olaratumab) in patients with advanced, metastatic soft tissue sarcoma (STS) at the Melbourne Theranostic Innovation Centre (MTIC) in Melbourne, Australia.
Mobile Version
